Ingredients | Amount Per Serving |
---|---|
(Astragalus membranaceus )
(root)
(Equivalent to 1,000 mg of whole herb)
(Astragalus 4:1 extract PlantPart: root Genus: Astragalus Species: membranaceus Note: Equivalent to 1,000 mg of whole herb )
|
250 mg |
(4'-methoxy-5'7-dihydroxyflavone)
(Chrysanthemum indicum L.)
|
100 mg |
Gelatin Note: capsule, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide (Alt. Name: SiO2)
Below is general information about the effectiveness of the known ingredients contained in the product Arimidrol. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
There is insufficient reliable information available about the effectiveness of methoxylated flavones.
Below is general information about the safety of the known ingredients contained in the product Arimidrol. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
POSSIBLY SAFE ...when used orally and appropriately. Doses of astragalus up to 60 grams daily for up to 4 months have been used without reported adverse effects (32920,33038,95909). ...when used intravenously. Infusion of doses up to 80 grams daily for up to 4 months under the supervision of a medical professional have been used with apparent safety (32811,32812,32828,95909). There is insufficient reliable information available about the safety of astragalus when used topically.
PREGNANCY AND LACTATION:
There is insufficient reliable information in humans.
However, astragaloside, a constituent of astragalus, has maternal and fetal toxic effects in animals (32881). Avoid using.
LIKELY SAFE ...when consumed orally in amounts typically found in foods (12078). There is insufficient reliable information available about the safety of methoxylated flavones when used in amounts greater than those in foods or when taken as a dietary supplement.
PREGNANCY AND LACTATION: LIKELY SAFE
when consumed orally in amounts typically found in foods (12078).
There is insufficient reliable information available about the safety of methoxylated flavones when used in amounts greater than those found in foods during pregnancy or breast-feeding; avoid using in amounts greater than those typically found in foods.
Below is general information about the interactions of the known ingredients contained in the product Arimidrol. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Theoretically, taking astragalus with antidiabetes drugs might increase the risk of hypoglycemia.
Details
|
Theoretically, astragalus might interfere with cyclophosphamide therapy.
Details
|
Theoretically, astragalus might interfere with immunosuppressive therapy.
Details
|
Theoretically, astragalus might increase levels and adverse effects of lithium.
Details
Animal research suggests that astragalus has diuretic properties (15103). Theoretically, due to this diuretic effect, astragalus might reduce excretion and increase levels of lithium.
|
In vitro evidence suggests that some methoxylated flavones have antiplatelet effects (12079,12083). Theoretically, methoxylated flavones might additive effects when used with anticoagulant or antiplatelet drugs.
Details
Some anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.
|
Some in vitro evidence suggests that methoxylated flavones might induce CYP1A2, possibly by increasing gene transcription (12078). However, other in vitro research has not shown this effect (100676). So far this interaction has not been reported in humans. Theoretically, concurrent use of methoxylated flavones and drugs metabolized by CYP1A2 might increase drug metabolism, decrease serum levels, and reduce effectiveness.
Details
Some drugs metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), Pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline (Slo-bid, Theo-Dur, others), zileuton (Zyflo), Zolmitriptan (Zomig), and others.
|
In vitro evidence suggests that methoxylated flavones might inhibit cytochrome P450 3A4 (CYP3A4). This effect seems to be structure-dependent, and does not occur with all methoxylated flavones (100676). So far this interaction has not been reported in humans. Theoretically, concurrent use of certain methoxylated flavones with drugs metabolized by CYP3A4 might result in increased drug levels and an increased risk for adverse effects.
Details
Some drugs metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), Pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline (Slo-bid, Theo-Dur, others), zileuton (Zyflo), Zolmitriptan (Zomig), and others.
|
In vitro, methoxylated flavones inhibit organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1 (106331). This may reduce the bioavailability of oral drugs that are substrates of OATP. However, this interaction has not been reported in humans.
|
In vitro evidence shows that some methoxylated flavones including tangeretin, nobiletin, and heptamethoxyflavone, inhibit P-glycoprotein (15327,94025). Theoretically, these methoxylated flavones might increase absorption and blood levels of drugs that are transported by P-glycoprotein.
Details
Some of these drugs include some chemotherapeutic agents (daunorubicin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir, saquinavir), H2 antagonists (cimetidine, ranitidine), some calcium channel blockers (diltiazem, verapamil), corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.
|
Below is general information about the adverse effects of the known ingredients contained in the product Arimidrol. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally and intravenously, astragalus root seems to be well tolerated.
Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.
Serious Adverse Effects (Rare):
Orally: A case report raises concerns about liver and kidney cysts with astragalus use.
Cardiovascular ...Orally, astragalus has reportedly been associated with lacunar angina in one clinical trial. However, this may not have been caused by astragalus (17355). In addition, rapid intravenous administration of astragalus has resulted in temporary palpitations (32812).
Dermatologic ...Intravenously, astragalus may cause rash, eczema, and pruritus (33034).
Gastrointestinal ...Orally, astragalus has reportedly been associated with enterocolitis and nausea in one clinical trial. However, these effects may not have been caused by astragalus (17355).
Genitourinary ...Orally, astragalus has reportedly been associated with vulvitis in one clinical trial. However, this effect may not have been caused by astragalus (17355).
Hepatic ...A case of high serum CA19-9 levels and small liver and kidney cysts has been reported for a 38-year-old woman who drank astragalus tea daily for one month. Levels returned to normal after one month, and cysts disappeared after ten months. Both symptoms returned following a resumption of astragalus use. The authors state that astragalus was the likely cause given the temporal relationship (90658).
Neurologic/CNS ...Rapid intravenous administration of astragalus has resulted in temporary dizziness (32812).
Pulmonary/Respiratory ...Orally, astragalus has reportedly been associated with rhinosinusitis and pharyngitis in one clinical trial. However, these effects may not have been caused by astragalus (17355).
Renal ...A case of high serum CA19-9 levels and small liver and kidney cysts has been reported for a 38-year-old woman who drank astragalus tea daily for one month. Levels returned to normal after one month, and cysts disappeared after ten months. Both symptoms returned following a resumption of astragalus use. The authors state that astragalus was the likely cause given the temporal relationship (90658).
General ...No adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.